Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis.
Five hyperthyroid patients (two men and three women) with typical features of subacute thyroiditis were treated with sodium ipodate (Oragrafin; 0.5 g, orally daily or every other day) for 15-60 days; the treatment was stopped when both serum T4 and T3 levels were normal. All patients studied demonstrated a prompt normalization of serum T3, improvement in clinical symptoms of hyperthyroidism, and/or weight gain. We observed no side-effects of treatment with sodium ipodate. Our data suggest that sodium ipodate is a safe and effective agent for management of hyperthyroidism in subacute thyroiditis.
Chopra
I J
IJ
Department of Medicine, University of California Center for the Health Sciences, Los Angeles 90024, USA.
van Herle
A J
AJ
Korenman
S G
SG
Viosca
S
S
Younai
S
S
D000328:Adult; D001323:Autoantibodies / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007487:Ipodate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013961:Thyroid Gland / Q000276:immunology / Q000378:metabolism; D013968:Thyroiditis, Subacute / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D013972:Thyrotropin / Q000097:blood*; D013974:Thyroxine / Q000097:blood*; D013997:Time Factors; D014284:Triiodothyronine / Q000097:blood*
D001323:Autoantibodies; D014284:Triiodothyronine; D013972:Thyrotropin; D007487:Ipodate; D013974:Thyroxine